



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Chronic Cough Related to Acute Viral Bronchiolitis in Children

CHEST Expert Panel Report



Anne B. Chang, MBBS, PhD, MPH; John J. Oppenheimer, MD; Bruce K. Rubin, MD; Miles Weinberger, MD, FCCP; and Richard S. Irwin, MD, Master FCCP; on behalf of the CHEST Expert Cough Panel

BACKGROUND: Acute bronchiolitis is common in young children, and some children develop chronic cough after their bronchiolitis. We thus undertook systematic reviews based on key questions (KQs) using the PICO (Population, Intervention, Comparison, Outcome) format. The KQs were: Among children with chronic cough (> 4 weeks) after acute viral bronchiolitis, how effective are the following interventions in improving the resolution of cough?: (1) Antibiotics. If so what type and for how long? (2) Asthma medications (inhaled steroids, beta₂ agonist, montelukast); and (3) Inhaled osmotic agents like hypertonic saline?

METHODS: We used the CHEST expert cough panel's protocol and the American College of Chest Physicians (CHEST) methodological guidelines and GRADE framework. Data from the systematic reviews in conjunction with patients' values and preferences and the clinical context were used to form these suggestions. Delphi methodology was used to obtain consensus.

RESULTS: Several studies and systematic reviews on the efficacy of the three types of interventions listed in the introduction were found but no data were relevant to our KQs. Thus, no recommendations on using the interventions above could be formulated.

CONCLUSIONS: The panel made several consensus-based suggestions and identified directions for future studies to advance the field of managing chronic cough post-acute bronchiolitis in children.

CHEST 2018; 154(2):378-382

KEY WORDS: cough; evidence-based medicine; guidelines

ABBREVIATIONS: KQ = key question; RCT = randomized controlled trial

AFFILIATIONS: From the Division of Child Health (Dr Chang), Menzies School of Health Research, Darwin, Australia; Respiratory and Sleep Department (Dr Chang), Lady Cilento Children's Hospital, Qld Uni of Technology, Brisbane, QLD, Australia; Division of Allergy and Immunology (Dr Oppenheimer), Department of Medicine, New Jersey Medical School, Pulmonary and Allergy Associates, Morristown, NJ; Division of Pulmonary, Allergy, and Critical Care Medicine (Dr Irwin), Department of Medicine, UMass Memorial Medical Center, Worcester, MA; Department of Pediatrics (Dr Rubin), Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA; and the Department of Pediatrics (Dr Weinberger), University of California San Diego, Rady Children's Hospital, San Diego, CA.

FUNDING/SUPPORT: A. B. C. is supported by an NHMRC practitioner fellowship [Grant 1058213] and holds multiple grants awarded from

the NHMRC related to diseases associated with pediatric cough and acute bronchiolitis. The views expressed in this publication are those of the authors and do not reflect the views of the NHMRC.

DISCLAIMER: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at <http://www.chestnet.org/Guidelines-and-Resources/Guidelines-and-Consensus-Statements/CHEST-Guidelines>.

CORRESPONDENCE TO: Anne B. Chang, MBBS, PhD, MPH, Division of Child Health, Lady Cilento Children's Hospital, South Brisbane, Brisbane, QLD, 4101 Australia; e-mail: annechang@ausdoctors.net
Copyright © 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

DOI: <https://doi.org/10.1016/j.chest.2018.04.019>

Summary of Suggestions

1. For children with chronic cough (> 4 weeks) after acute viral bronchiolitis, we suggest that the cough be managed according to the CHEST pediatric chronic cough guidelines (Ungraded Consensus-based Statement).

Remark: These include the evaluation for the presence of cough pointers and the use of 2 weeks of antibiotics targeted to common respiratory bacteria (*Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*) and local antibiotic sensitivities managing in children with wet or productive cough unrelated to an underlying disease and without any specific cough pointers (eg, coughing with feeding, digital clubbing).

2. For children with chronic cough (> 4 weeks) after acute viral bronchiolitis, we suggest that asthma medications not be used for the cough unless other evidence of asthma is present (Ungraded Consensus-based Statement).

Remark: Symptoms of asthma include the presence of recurrent wheeze and/or dyspnea.

3. For children with chronic cough (> 4 weeks) after acute viral bronchiolitis, we suggest that inhaled osmotic agents not be used (Ungraded Consensus-based Statement).

Introduction

In pediatrics, bronchiolitis is a clinical diagnosis characterized by tachypnea, wheeze and/or crepitations/crackles in children (aged < 2 years) following an upper respiratory illness.^{1,2} Worldwide, bronchiolitis is one of the most common acute lower respiratory tract infections in very young children¹ and the most common cause of hospitalization in those aged < 1 year.² Bronchiolitis is characterized by extensive inflammation of the airways accompanied by increased mucus production and necrosis of airway epithelial cells and other pathobiology, the discussion of which is beyond the scope of this article. It is primarily caused by infection of the respiratory epithelial cells by a variety of viruses (eg, respiratory syncytial virus, adenovirus, influenza, parainfluenza, human metapneumovirus, rhinovirus and coronavirus).^{1,2}

Materials and Methods

We undertook the systematic reviews based on the protocol⁹ established by selected members of the CHEST expert cough panel. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement for reporting. The KQs were framed by this paper's main authors.

Bronchiolitis is a self-limiting condition in most children but some may have ongoing symptoms post the acute episode. A systematic review found that in children with bronchiolitis, 90% were cough-free by day 21 (mean time of cough resolution was 8-15 days).³ Those with chronic symptoms (after 4 weeks) possibly represent a different clinical problem. Sometimes it is termed post-bronchiolitis syndrome.⁴ The previous UK-based Scottish Intercollegiate Guidelines Network guideline⁵ refers to post-bronchiolitis syndrome as the presence of any respiratory symptoms that includes chronic cough. However, in the most recent UK National Institute for Health and Care Excellence guidelines, 'post-bronchiolitis syndrome' is implied as "a chronic, relapsing episodic wheeze with subsequent viral infections may occur over the ensuing 6 months or so."¹

Given the high prevalence of bronchiolitis¹ and the potential impact of chronic cough on the quality of life,⁶ multiple doctor visits,⁷ and adverse effects from inappropriate use of medications,⁸ the American College of Chest Physicians (CHEST) panel considered several questions relating to chronic cough (> 4 weeks duration) post-bronchiolitis to be important.

Using the PICO (Population, Intervention, Comparison, Outcome) framework, we performed systematic reviews to address key questions (KQs) relating to etiologies of cough in children. Here, we present the systematic reviews for the KQs, summary of the evidence, and the formulated recommendations based upon these findings utilizing CHEST's cough guidelines methods and framework.⁹ The 3 KQs addressed were:

KQ1: In children with chronic cough (> 4 weeks) after acute viral bronchiolitis, are antibiotics effective in improving the resolution of cough? If so, what antibiotics and for how long?

KQ2: In children with chronic cough (> 4 weeks) after acute viral bronchiolitis, are asthma medications (eg, inhaled and oral corticosteroids, beta₂ agonist, montelukast) effective in improving the resolution of cough? If so, what and for how long?

KQ3: In children with chronic cough due to acute viral bronchiolitis, are inhaled osmotic agents like hypertonic saline effective in improving the resolution of cough?

Study Identification and Eligibility Criteria

Searches for the three systematic reviews were externally undertaken by librarians (Nancy Harger, MLS, and Judy Nordberg, MLS) from the University of Massachusetts Medical School using the search strategies outlined in [e-Appendix 1](#). We included only studies published in English. Duplicates found between Scopus and PubMed

searches were identified and removed by the librarians before sending the abstracts to the two authors (A. B. C. and J. J. O.) who independently reviewed the abstracts.

Data Extraction and Quality Assessment

The two reviewers fully agreed on which full-text articles to retrieve to assess for potentially eligible studies. It was planned that disagreements that could not be resolved by consensus would be adjudicated by a third reviewer (R. S. I.), but there were no disagreements. As previously done,^{10,11} it was also planned that data would have been extracted by a single author and checked by a second and that a GRADE-based quality assessment independently undertaken for any randomized controlled trial (RCT). However, as there were no relevant studies, our planned methods were not relevant.

Recommendation/Suggestion Framework

We used a standard method⁹ as previously described¹²: “The methodology used by the CHEST Guideline Oversight Committee to select the Expert Cough Panel Chair and the international panel of experts, perform the synthesis of the evidence and develop the recommendations and suggestions has been published.^{9,13} Key questions and parameters of eligibility were developed for this topic. Existing guidelines, systematic reviews, and primary studies were

assessed for relevance and quality, and were used to support the evidence-based graded recommendations or suggestions. A highly structured consensus-based Delphi approach was employed to provide expert advice on all guidance statements. The total number of eligible voters for each guideline statement varied based on the number of managed individuals recused from voting on any particular statement(s) because of their potential conflicts of interest. Transparency of process was documented. Further details of the methods have been published elsewhere.^{9,13} Consistent with recent recommendations from the National Academy of Medicine (previously referred to as the Institute of Medicine), the Panel conducted a comprehensive, systematic review of the literature to provide the evidence base for this guideline.” During the Delphi approach, those with a ‘conflict of interest’ were not permitted to vote. The committee has a patient representative who approved the suggestions/recommendations during the voting process.

The CHEST approach separates the process of rating the quality of evidence from that of determining the strength of recommendation. The quality of evidence is based on the five domains of risk of bias, inconsistency, indirectness, reporting bias, and imprecision. Where there is insufficient evidence, ‘suggestions’ are formulated instead of recommendations.

Results

The search results and Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagrams for all KQs are presented in e-Appendix 1. The duration of cough relating to the various interventions, including antibiotics (KQ1), asthma medications (KQ2), and hypertonic saline (KQ3), was examined as an outcome in the National Institute for Health and Care Excellence guideline.¹ However, none of the data fulfilled our KQ criteria as in all the studies, children with acute bronchiolitis were recruited and none of the studies reported on the duration of cough at or beyond 4 weeks. Combining this with our own searches, the summary is presented below.

Summary of Evidence and Interpretation

The single paper included in KQ1 was a recently updated Cochrane systematic review.⁴ The systematic review compared antibiotics with controls (placebo or no treatment) administered in the post-acute phase of bronchiolitis (> 14 days) but included antibiotics started in the acute phase. The Cochrane review concluded that “there was insufficient evidence to inform whether antibiotics should be used to treat or prevent persistent respiratory symptoms in the post-acute phase of bronchiolitis.”

There were no prospective studies that have specifically recruited children with chronic cough post-bronchiolitis. A study involving only Aboriginal Australian children hospitalized for bronchiolitis described that the presence of cough at follow-up (at 3 weeks post-discharge) was significantly associated

with future identification of radiological bronchiectasis (OR, 3 [95% CI, 1.1-7]; $P = .03$).¹⁴ However, these data cannot be applied to the general mainstream population, given the narrow population profile.

In our previous systematic reviews on the etiology¹¹ and the use of pediatric-specific cough pathways when managing children with chronic cough,¹⁵ none of the various cohorts mentioned whether the chronic cough was related to bronchiolitis. However, given the young median age in some cohorts, it is possible (although remains unknown) how many of these cohorts included children with recent bronchiolitis. Given the burden of chronic cough including the negative effect on quality of life,⁶ until more data specific to chronic cough post-acute bronchiolitis become available, we suggest that these children are managed in accordance with current CHEST pediatric cough guidelines.^{11,15,16} Of the total of 23 recommendations/suggestions from these guidelines, the ones most likely applicable are the recommendations to evaluate for the presence of cough pointers and the use of 2 weeks of antibiotics targeted to common respiratory bacteria (*Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*) and local antibiotic sensitivities managing in children with wet or productive cough unrelated to an underlying disease and without any specific cough pointers (eg, coughing with feeding, digital clubbing).^{15,16}

No relevant papers were identified for KQ2 or KQ3. Post-publication of the American Academy of Pediatrics² and Scottish Intercollegiate Guidelines

Network¹ bronchiolitis guidelines, our search identified several other RCTs that also found that hypertonic saline was not efficacious for the various clinical outcomes examined (none examined for development or treatment of chronic cough) in children with bronchiolitis. In the context that neither asthma medications nor hypertonic saline is efficacious for acute bronchiolitis,¹ both groups of interventions are also not recommended for post-bronchiolitis chronic cough. However, as current data suggest that the incidence of asthma is increased post-acute viral bronchiolitis,¹⁷ clinicians should assess for the presence of the symptoms and signs of asthma (eg, recurrent wheeze and dyspnea responsive to beta₂ agonists), which is in-line with recommendations in current CHEST chronic cough guidelines.^{11,15,16}

Using CHEST's framework, as our systematic reviews found no data specific to our KQs, only suggestions could be formulated.

1. For children with chronic cough (> 4 weeks) after acute viral bronchiolitis we suggest that the cough be managed according to the CHEST pediatric chronic cough guidelines (Ungraded Consensus-based Statement).

Remark: These include the evaluation for the presence of cough pointers and the use of 2 weeks of antibiotics targeted to common respiratory bacteria (*Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*) and local antibiotic sensitivities managing in children with wet or productive cough unrelated to an underlying disease and without any specific cough pointers (eg, coughing with feeding, digital clubbing).^{15,16}

2. For children with chronic cough (> 4 weeks) after acute viral bronchiolitis we suggest that asthma medications not be used for the cough unless other evidence of asthma is present (Ungraded Consensus-based Statement).

Remark: Symptoms of asthma include the presence of recurrent wheeze and/or dyspnea.

3. For children with chronic cough (>4 weeks) after acute viral bronchiolitis we suggest that inhaled osmotic agents not be used (Ungraded Consensus-based Statement).

Areas for Further Research

To advance and improve knowledge regarding the management of chronic cough post-acute bronchiolitis in children, we suggest other areas of research.

1. There are currently little data regarding the transition from acute to chronic cough.¹⁸ While studies have reported that some children with persistent symptoms post-bronchiolitis, their individual outcomes are unknown. Thus, we suggest multi-center cohort studies involving children with bronchiolitis of different severity in various clinical settings (rural-remote vs urban) to evaluate their individual outcomes focusing on cough and the etiology immediately post-bronchiolitis.

2. RCTs should include various interventions (eg, antibiotics for wet cough and inhaled or short course oral corticosteroids for dry cough post-acute bronchiolitis) that may be efficacious for chronic cough post-bronchiolitis. The RCTs should utilize validated cough outcomes and a priori definitions.

3. Studies on whether tobacco smoke exposure (in utero, post-natal, and environmental) and air quality contribute to the development of chronic cough post-bronchiolitis such as large cohort and/or case control studies in different settings.

4. Are there specific risk factors and/or pathogens that are likely to result in post-bronchiolitis chronic cough? For example, does the presence of polymicrobial (eg, mixed viral-bacteria) pathogens in the airways increase the risk of developing chronic cough?

Acknowledgments

Author contributions: All key questions were voted on by all authors. A. B. C. drafted the manuscript and undertook the systematic review with J. J. O. J. O., B. K. R., M. W., and R. S. I. modified the manuscript. The entire CHEST panel voted on the recommendations.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following: A. B. C. is an UpToDate author and reviewer; member of the data safety monitoring board for a vaccine study (Glaxo); and advisor for study design of an unlicensed product (Merck). J. J. O. is member of the Board of Directors of the American Board of Allergy and Immunology; Associate Editor for *Annals of Allergy and Allergy Watch*; reviewer for UpToDate; clinical research for AstraZeneca, Boehringer Ingelheim, Glaxo, Medimmune, and Novartis; member of the Adjudication Committees for AstraZeneca and Novartis; member of the Data safety monitoring board for The Ohio State University; and has served as a consultant Glaxo, Myelin, Church and Dwight, and Meda. R. S. I. has no financial or intellectual conflicts of interest regarding the content of this manuscript; moreover, while R.S.I. is the Editor in Chief of CHEST, the review and all editorial decisions regarding the manuscript were independently made by others. None declared: (M. M. W., B. K. R., G. C. C.).

Role of sponsors: CHEST was the sole supporter of these guidelines, this article, and the innovations addressed within.

Collaborating authors: Todd M. Adams, MD (Webhannet Internal Medicine Associates of York Hospital), Kenneth W. Altman, MD, PhD (Baylor College of Medicine, Houston, TX), Elie Azoulay, MD, PhD (University of Paris, Paris, France), Alan F. Barker, MD (Oregon Health & Science University, Portland, OR), Surinder S. Birring, MBChB, MD (Division of Asthma, Allergy and Lung Biology, King's College London, Denmark Hill, London, United Kingdom), Fiona Blackhall, MD, PhD (University of Manchester, Department of Medical Oncology, Manchester, England), Donald C. Bolser, PhD

(College of Veterinary Medicine, University of Florida, Gainesville, FL), Louis-Philippe Boulet, MD, FCCP (Institut universitaire de cardiologie et de pneumologie de Québec, Québec, [IUCPQ], QC, Canada), Sidney S. Braman, MD, FCCP (Mount Sinai Hospital, New York, NY), Christopher Brightling, MBBS, PhD, FCCP (University of Leicester, Glenfield Hospital, Leicester, United Kingdom), Priscilla Callahan-Lyon, MD (Adamstown, MD), Anne B. Chang, MBBS, PhD, MPH (Royal Children's Hospital, Brisbane, QLD, Australia), Terrie Cowley (The TMJ Association, Milwaukee, WI), Paul Davenport, PhD (Department of Physiological Sciences, University of Florida, Gainesville, FL), Satoru Ebihara, MD, PhD (Department of Rehabilitation Medicine, Toho University School of Medicine, Tokyo, Japan), Ali A. El Solh, MD, MPH (University at Buffalo, State University of New York, Buffalo, NY), Patricio Escalante, MD, MSc, FCCP (Mayo Clinic, Rochester, MN), Stephen K. Field, MD (University of Calgary, Calgary, AB, Canada), Dina Fisher, MD, MSc (University of Calgary, Respiratory Medicine, Calgary, AB, Canada), Cynthia T. French, PhD, FCCP (UMass Memorial Medical Center, Worcester, MA), Peter Gibson, MBBS (Hunter Medical Research Institute, NSW, Australia), Philip Gold, MD, MACP, FCCP (Loma Linda University, Loma Linda, CA), Susan M. Harding, MD, FCCP (Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL), Anthony Harnden, MB ChB, MSc (University of Oxford, Oxford, England), Adam T. Hill, MB ChB, MD (Royal Infirmary and University of Edinburgh, Edinburgh, Scotland), Richard S. Irwin, MD, Master FCCP (UMass Memorial Medical Center, Worcester, MA), Peter J. Kahrilas, MD (Feinberg School of Medicine, Northwestern University, Chicago, IL), Joanne Kavanagh, MBChB, (Division of Asthma, Allergy and Lung Biology, King's College London, Denmark Hill, London, United Kingdom), Karina A. Keogh, MD (Mayo Clinic, Rochester, MN), Kefang Lai, MD, PhD (First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China), Andrew P. Lane, MD (Johns Hopkins University School of Medicine, Baltimore, MD), Kaiser Lim, MD (Mayo Clinic, Rochester, MN), J. Mark Madison, MD, FCCP (UMass Memorial Medical Center, Worcester, MA), Mark A. Malesker, PharmD, FCCP (Creighton University School of Pharmacy and Health Professions, Omaha, NE), Stuart Mazzone, PhD, FCCP (University of Melbourne, Victoria, Australia), Lorcan McGarvey, MD (The Queens University Belfast, Belfast, United Kingdom), Joshua P. Metlay, MD, PhD (Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA), Alex Molasaitis, PhD, MSc, RN (Hong Kong Polytechnic University, Hong Kong, China), Abigail Moore, BM BCH (University of Oxford, Oxford, England), M. Hassan Murad, MD, MPH (Mayo Clinic, Rochester, MN), Mangala Narasimhan, DO, FCCP (Hofstra-Northwell Health, Manhasset, NY), Huong Q. Nguyen, PhD, RN (Kaiser Permanente, Pasadena, CA), Peter Newcombe, PhD (School of Psychology University of Queensland, QLD, Australia), John Oppenheimer, MD (UMDNJ-Rutgers University, Newark, NJ), Marcos I. Restrepo, MD, MSc, FCCP (South Texas Veterans Health Care System, San Antonio, TX), Mark Rosen, MD, Master FCCP (Icahn School of Medicine at Mount Sinai, New York, NY), Bruce Rubin, MEng, MD, MBA (Virginia Commonwealth University, Richmond, VA), Jay H. Ryu, MD, FCCP (Mayo Clinic, Rochester, MN), Sonal Singh, MD, MPH (UMass Memorial Medical Center, Worcester, MA), Maeve P. Smith, MB ChB, MD (University of Alberta, Edmonton, AB, Canada), Susan M. Tarlo, MBBS, FCCP (Toronto Western Hospital, Toronto, ON, Canada), Julie Turmel, PhD (Quebec Heart and Lung Institute, Laval University, Québec, QC, Canada), Anne E. Vertigan, PhD, MBA, BAppSc (SpPath) (John Hunter Hospital, NSW, Australia), Gang Wang, MD, PhD (Sichuan University, West China Hospital, Chengdu, China), Miles Weinberger, MD, FCCP (Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, CA).

Endorsements: This guideline has been endorsed by the American Association for Respiratory Care (AARC), American College of

Allergy, Asthma and Immunology (ACAAI), and American Thoracic Society (ATS).

Other contributions: The authors are grateful to Nancy Harger, MLS, and Judy Nordberg, MLS, Education and Clinical Services Librarians working in the University of Massachusetts Medical School Library in Worcester, MA, who undertook all the searches for these systematic reviews.

References

1. National Institute for Health and Care Excellence (NICE). Bronchiolitis: diagnosis and management in children. <https://www.nice.org.uk/Guidance/NG9>. Accessed August 29, 2017.
2. Ralston S, Lieberthal AS, Meissner HC, et al. clinical practice guideline: the diagnosis, management and prevention of bronchiolitis. *Pediatrics*. 2014;134(5):e1474-e1502.
3. Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: systematic review. *BMJ*. 2013;347:f7027.
4. McCallum GB, Plumb EJ, Morris PS, et al. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. *Cochrane Database Syst Rev*. 2017;8:CD009834.
5. SIGN. Bronchiolitis in children. <http://www.sign.ac.uk/pdf/sign91.pdf>. Accessed August 16, 2014.
6. Chang AB, Robertson CF, van Asperen PP, et al. A multi-centre study on chronic cough in children: burden and etiologies based on a standardized management pathway. *Chest*. 2012;142(4):943-950.
7. Marchant JM, Newcombe PA, Juniper EF, et al. What is the burden of chronic cough for families? *Chest*. 2008;134(2):303-309.
8. Thomson F, Masters IB, Chang AB. Persistent cough in children—overuse of medications. *J Paediatr Child Health*. 2002;38(6):578-581.
9. Lewis SZ, Diekemper RL, French CT, et al. Methodologies for the development of the management of cough: CHEST guideline and expert panel report. *Chest*. 2014;146(5):1395-1402.
10. Chang AB, Oppenheimer JJ, Weinberger MM, et al. Children with chronic wet or productive cough -treatment and investigations: a systematic review. *Chest*. 2016;149(1):120-142.
11. Chang AB, Oppenheimer JJ, Weinberger MM, et al. Etiologies of chronic cough in pediatric cohorts: CHEST Guideline and Expert Panel Report. *Chest*. 2017;152(3):607-617.
12. Vertigan AE, Murad MH, Pringsheim T, et al. Somatic cough syndrome (previously referred to as psychogenic cough) and tic cough (previously referred to as habit cough) in adults and children: CHEST Guideline and Expert Panel Report. *Chest*. 2015;148(1):24-31.
13. Irwin RS, French CT, Lewis SZ, et al. Overview of the management of cough: CHEST Guideline and Expert Panel Report. *Chest*. 2014;146(4):885-889.
14. McCallum GB, Morris PS, Chatfield MD, et al. Outcomes of risk factors of indigenous infants hospitalised with bronchiolitis. *Pediatr Pulmonol*. 2016;51(6):613-623.
15. Chang AB, Oppenheimer JJ, Weinberger MM, et al. Use of management pathways or algorithms in children with chronic cough: CHEST Guideline and Expert Panel Report. *Chest*. 2017;151(4):884-890.
16. Chang AB, Oppenheimer JJ, Weinberger MM, et al. Management of children with chronic wet cough and protracted bacterial bronchitis: CHEST Guideline and Expert Panel Report. *Chest*. 2017;151(4):884-890.
17. Gaffin JM, Phipatanakul W. The calculated risk of childhood asthma from severe bronchiolitis. *J Allergy Clin Immunol Pract*. 2017;5(1):97-98.
18. O'Grady KF, Drescher BJ, Goyal V, et al. Chronic cough postacute respiratory illness in children: a cohort study. *Arch Dis Child*. 2017;102(11):1044-1048.